Medindia
Advertisement

Bone Drugs may Not Protect Osteoporotic Women from Breast Cancer: Study

by Sheela Philomena on August 12, 2014 at 2:07 PM
Font : A-A+

 Bone Drugs may Not Protect Osteoporotic Women from Breast Cancer: Study

Bisphosphonates may not protect women from breast cancer as had been thought, states new study.

The drugs' protective effect was widely assumed after several observational studies showed that women who took them were less likely to get breast cancer.

Advertisement

But when researchers assessed the effect of two of the most widely used osteoporosis drugs - sold under the brand names, Fosamax and Reclast - in two large randomized clinical trials, neither drug protected women with osteoporosis from getting breast cancer. The results were published August 11, 2014, in JAMA Internal Medicine.

The researchers said the link found in the previous observational studies between taking the drugs and having a lower incidence of breast cancer may be due to a third factor, low estrogen.
Advertisement

Since having low estrogen both weakens bones and protects against most breast cancers, the women most likely to be prescribed drugs for osteoporosis are usually also at lower risk for breast cancer.

"They may have seen a lower risk of breast cancer in women using bisphosphonates in the earlier observational studies because those women had a lower risk of breast cancer to begin with," said Trisha Hue, PhD, lead author of the study.

"Post-menopausal women with osteoporosis usually have low estrogen levels," said Hue, an epidemiologist with the San Francisco Coordinating Center, a partnership between the CPMC Research Institute and the UCSF Department of Epidemiology & Biostatistics. "Lower levels of estrogen are strongly associated with a lower risk of breast cancer."

Steven Cummings, MD, a co-author of the paper, a UCSF emeritus professor of medicine and director of the San Francisco Coordinating Center, said women should not take these drugs thinking they will protect them from breast cancer.

"Post-menopausal women should continue taking these drugs for the prevention of fractures, but they should not use bisphosphonates for the prevention of primary breast cancer," said Cummings, also a senior scientist at the CPMC Research Institute.

The data analyzed in the study came from two double blind, placebo controlled clinical trials. In both trials, women who received bisphosphonates had a slightly higher but statistically non-significant incidence of breast cancer.

The Fracture Intervention Trial (FIT) randomly assigned 6,459 women from the United States aged 55 to 81 to alendronate or a placebo for an average follow up of 3.8 years; 1.8 percent of the women who received the drug developed breast cancer, while 1.5 percent of those given a placebo developed the disease.

The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) randomly assigned 7,765 women from the United States, Canada, Asia, Europe and South America aged 65 to 89 to annual intravenous zoledronic acid or a placebo for an average follow up of 2.8 years; .87 percent of women who received the drug developed breast cancer, while .77 percent of those given a placebo developed the disease.

Women in either study who had recurrent breast cancer or reported a history of breast cancer were excluded from the analysis.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Sedentary Behavior Precipitates Night-Time Hot Flashes
Gonorrhea
World Alzheimer's Day 2021 - 'Know Dementia, Know Alzheimer's
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Mastitis Infantile Cortical Hyperostosis Breasts - Structures and Types Breast Lumps Breast Lumps-Screening Drugs Banned in India Renal Osteodystrophy / Mineral Bone Disorder Breast Enhancement Oil 

Recommended Reading
Screening for Breast Cancer with Clinical Breast Examination
Clinical breast examination is a simple and inexpensive method of detecting breast cancer ......
Screening for Osteoporosis
The risk of suffering from osteoporotic fractures is 30-50% in women and 15 to 30% in men. ......
Quiz on Osteoporosis
Osteoporosis is a debilitating condition that affects all the bones. However, the bones of the hip, ...
Benefits Of Bisphosphonates In People With Osteoporosis
Research says the risk of atypical fractures from taking bisphosphonates in people with ......
Breast Enhancement Oil
Breasts contain mammary glands which produce and secrete milk for feeding and nourishing babies. Tho...
Breast Lumps
Most breast lumps are caused by hormonal changes in a woman and may not be cancerous. Common causes ...
Breast Lumps-Screening
Breast lumps must never be neglected but instead be subjected to medical examination to rule out ......
Breasts - Structures and Types
Different stages of breast development in women and an in-depth look at the breast/bust and its ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Infantile Cortical Hyperostosis
Infantile Cortical Hyperostosis is a disease of unknown cause, where bizarre thickening of the corti...
Mastitis
Mastitis is a common cause of tenderness, swelling and pain in breast, owing to inflammation in the ...
Renal Osteodystrophy / Mineral Bone Disorder
Renal Osteodystrophy which is referred to as Mineral Bone Disorder is a result of imbalance in calci...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use